To compare the relative effectiveness of angiotensinconverting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in reducing cardiovascular mortality in chronic hemodialysis patients, we conducted an observational analysis of all patients initiated on ACEI or ARB therapy undergoing chronic hemodialysis at a large dialysis provider. Survival curves with mortality hazard ratios (HRs) were generated using the Kaplan-Meier method and Cox regression. Outcomes were compared using inverse probability of treatment weighting and propensity score matching. Over 6 years, 22,800 patients were newly initiated on an ACEI and 5828 on an ARB after at least 60 days of chronic hemodialysis. After adjustment for baseline cardiovascular risk factors, there was no significant difference in the risk of cardiovascular, all-cause, or cerebrovascular mortality in patients initiated on an ARB compared with an ACEI (HR of 0.96). A third of 28,628 patients, newly started on an ACEI or ARB, went on to another antihypertensive medication in succession. After adjustment for risk factors, 701 patients initiated on combined ACEI and ARB therapy (HR of 1.45) or 6866 patients on ACEI and non-ARB antihypertensive agent (HR of 1.27) were at increased risk of cardiovascular death compared with 1758 patients initiated on an ARB and non-ACEI antihypertensive therapy. Thus, an ARB, in combination with another antihypertensive medication (but not an ACEI), may have a beneficial effect on cardiovascular mortality. As observational studies may be confounded by indication, even when adjusted, randomized clinical trials are needed to confirm these findings. More than 20,000 patients on maintenance dialysis are expected to die from cardiovascular disease this year. The risk of cardiovascular events in end-stage renal disease (ESRD) is 3.4-fold higher than that of the general population.
To compare the relative effectiveness of angiotensinconverting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in reducing cardiovascular mortality in chronic hemodialysis patients, we conducted an observational analysis of all patients initiated on ACEI or ARB therapy undergoing chronic hemodialysis at a large dialysis provider. Survival curves with mortality hazard ratios (HRs) were generated using the Kaplan-Meier method and Cox regression. Outcomes were compared using inverse probability of treatment weighting and propensity score matching. Over 6 years, 22,800 patients were newly initiated on an ACEI and 5828 on an ARB after at least 60 days of chronic hemodialysis. After adjustment for baseline cardiovascular risk factors, there was no significant difference in the risk of cardiovascular, all-cause, or cerebrovascular mortality in patients initiated on an ARB compared with an ACEI (HR of 0.96). A third of 28,628 patients, newly started on an ACEI or ARB, went on to another antihypertensive medication in succession. After adjustment for risk factors, 701 patients initiated on combined ACEI and ARB therapy (HR of 1.45) or 6866 patients on ACEI and non-ARB antihypertensive agent (HR of 1.27) were at increased risk of cardiovascular death compared with 1758 patients initiated on an ARB and non-ACEI antihypertensive therapy. Thus, an ARB, in combination with another antihypertensive medication (but not an ACEI), may have a beneficial effect on cardiovascular mortality. As observational studies may be confounded by indication, even when adjusted, randomized clinical trials are needed to confirm these findings.
More than 20,000 patients on maintenance dialysis are expected to die from cardiovascular disease this year. The risk of cardiovascular events in end-stage renal disease (ESRD) is 3.4-fold higher than that of the general population. 1 Although risk factors for coronary artery disease (CAD), such as diabetes and hypertension, are prevalent among ESRD patients, conventional risk factors alone fail to explain all of the excess cardiovascular mortality in epidemiological studies. 2 Furthermore, modification of these risk factors has not been shown so far to be effective in reducing cardiovascular risk in ESRD. [3] [4] [5] Consequently, there is a need to evaluate alternate therapies that could potentially moderate cardiovascular disease progression in the dialysis population.
Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin type 1 (AT 1 ) receptor blockers (ARBs) reduce cardiovascular events within the general population. [6] [7] [8] [9] [10] [11] [12] [13] [14] The comparative effectiveness of ACEIs and ARBs in reducing cardiovascular mortality in patients at risk for cardiovascular disease is currently controversial, 10 as is the efficacy of combined ACEI and ARB therapy. 10, 14 Even less is known about the relative efficacy and safety of ACEIs and ARBs in ESRD, as only a few studies have examined the individual efficacy of ACEIs or ARBs versus no treatment. [15] [16] [17] [18] There have been no comparative effectiveness studies between ACEIs and ARBs in the ESRD patient population to date, despite the widespread prescription of these drugs among dialysis patients. 19, 20 To compare the effects of ACEIs and ARBs on cardiovascular mortality in chronic hemodialysis (CHD) patients, we conducted an observational analysis of outcomes in all patients undergoing CHD at a large dialysis provider, who were initiated on therapy with an ACEI, ARB, or both an ACEI and an ARB.
RESULTS
We surveyed 291,607 ESRD patients who received chronic dialysis at Fresenius Medical Care America over a 6-year period. Among this population, 22,800 CHD patients were newly initiated on an ACEI and 5828 patients on an ARB after at least 60 days of CHD (9.8% of the population). Patients were followed up for an average of 1.26 years (ACEI users: 1.27 years; ARB users: 1.24 years).
When compared with ARB users, the ACEI group was more likely to be male, black, and diabetic, and more likely to have documented CAD, congestive heart failure, or history of stroke (Table 1) . Baseline blood pressures were 2 mm Hg systolic and 1 mm Hg diastolic lower in the ACEI group when compared with the ARB group (Po0.0001); however, blood pressure responses to ACEI and ARB initiation were not different. These differences were successfully balanced after propensity score adjustment (see propensity score P-value in Table 1 ). The number of events for the three mortality outcomes (cardiovascular, all-cause, and cerebrovascular death) and for adverse events (hyperkalemia, orthostatic hypotension, risk of fall) is listed in Table 2 .
In unadjusted models, initiation of an ARB (versus ACEI) was associated with a significantly decreased risk of cardiovascular death (hazard ratio (HR) ¼ 0.87; 95% confidence interval 0.80-0.95) and death due to any cause (HR ¼ 0.90; 95% confidence interval 0.85-0.95), but not with cerebrovascular mortality (Figure 1a and Table 2 ). After adjustment for baseline covariates and weighting for the inverse probability of treatment, there was no significant difference in the risk of cardiovascular, all-cause, or cerebrovascular mortality in patients initiated on an ARB versus ACEI (Figure 1b ). There were also no statistical interaction effects by patient characteristic on mortality (Supplementary Figure S1 online). In a matched propensity score cohort, 4880 patients treated with ACEI were compared with 4880 patients treated with ARB. Baseline characteristics were similar in the matched cohort (Supplementary  Table S1 online), and HRs were not different from those obtained after covariate adjustment and weighted for the inverse probability of treatment (Table 2) .
Combination (ACEI+ARB) versus (ACEI+other antihypertensive) versus (ARB+other antihypertensive)
Overall, 33% of patients (9325 of 28,628) who were newly started on an ACEI or ARB went on to initiate another antihypertensive medication in succession (Table 3) . Within this subgroup, the second drug in 701 patients also inhibited the renin-angiotensin axis such that these patients took combination therapy (ACEI þ ARB). A total of 8624 patients were initiated on a non-renin-angiotensin-blocking agent in the setting of continued ACEI (ACEI þ non-ARB, n ¼ 6866) or ARB (ARB þ non-ACEI, n ¼ 1758) use. Patients were followed up for an average of 1.46 years (ACEI þ ARB users: 1.46 years; ACEI þ non-ARB users: 1.47 years; ARB þ non-ACEI users: 1.43 years).
Patients initiated on combination ACEI and ARB therapy were older, were more likely to be black, diabetic, have had congestive heart failure, have CAD, and to take antiplatelet drugs, and took more antihypertensive medication than did patients initiated on an ACEI or ARB with another class of antihypertensive therapy. No statistically significant differences in baseline blood pressure (Table 3) or lowering of blood pressure over time were evident among the three treatment groups. Implementation of propensity scores removed most statistical differences in baseline characteristics between treatment groups, except for age and statin use; however, the differences for these parameters were of little clinical significance. The number of events for mortality and adverse events within this part of the analysis is listed in Table 4 . Differences in outcomes were not statistically different among the groups in the unadjusted model (Table 4 and Figure 2a ). After adjustment for baseline covariates and weighting for the inverse probability of treatment, combination ACEI and ARB therapy was statistically significantly associated with the highest risk of cardiovascular death, whereas ARB þ non-ACEI anti-hypertensive therapy was associated with the lowest risk of cardiovascular death among the three groups (Table 4 and Figure 2b 
Adverse events
No statistical differences in the risk of hyperkalemia, post-dialysis orthostatic hypotension, or fall were noted among any of the groups (Tables 2 and 4 ).
DISCUSSION
We examined the relationship between the new initiation of an ACEI or ARB and cardiovascular deaths in 422,000 CHD patients followed for up to 2 years. After adjustment for risk factors, there was no significant difference in the risk of cardiovascular, all-cause, or cerebrovascular mortality in patients initiated on an ARB versus ACEI. In those patients who required another anti-hypertensive medication in addition to either an ACEI or an ARB, combination ACEI þ ARB treatment was associated with the highest cardiovascular mortality. On the other hand, ARB alone with the addition of a non-renin-angiotensin antihypertensive was associated with improved cardiovascular survival.
Both ACEIs and ARBs are effective anti-hypertension medications that decrease morbidity and mortality through normalization of high blood pressure. 21, 22 Although there are no direct comparisons between the two classes of drugs in patients with chronic kidney disease, the current body of evidence, albeit limited, supports cardiovascular benefit from ARBs, but the effectiveness of ACEIs has yet to be substantiated. [6] [7] [8] [9] [10] [11] [12] [13] [14] In particular, (1) fosinopril (ACEI) did not significantly reduce cardiovascular events in CHD patients in the randomized trial FOSInopril in DIALysis study (n ¼ 397); 17 (2) ARBs significantly decreased cardiovascular events and mortality when compared with untreated patients (n ¼ 80) in a trial by Takahashi et al.;
23 and (3) Suzuki et al. 24 observed a significant 49% decrease in fatal and non-fatal cardiovascular events in a randomized trial of ARB versus no ARB (n ¼ 360). We found that patients on an ARB experienced small, non-significant survival, and cardiovascular benefits when compared with an ACEI after adjustment for baseline patient characteristics.
To further explore the potential clinical impact of blocking the renin-angiotensin system with drugs with distinct biological effects, we examined the comparative effectiveness of ACEIs and ARBs used singly or in combination in ESRD patients undergoing hemodialysis. Studies of combined ACEI and ARB use in patients without chronic kidney disease have provided conflicting data with respect to cardiovascular benefit and some concern for harm. In Candesartan Heart Failure-Assessment of moRtality and Morbidity (CHARM)-added, randomization to candesartan (ARB) was associated with a reduced risk of cardiovascular death or hospitalization in patients already taking an ACEI. 14 In the Val-HeFT (Valsartan Heart Failure Trial), randomization to valsartan improved morbidity in congestive heart failure patients taking an ACEI or a b-blocker, but worsened morbidity and mortality in patients previously taking both an ACEI and a b-blocker. 12 In the VALIANT (Valsartan in Acute Myocardial Infarction Trial) and ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) studies, 6, 7 combination ACEI and ARB therapy lowered blood pressure and increased the risk for hypotension without improving cardiovascular outcomes; furthermore, ONTARGETreported combination therapy showed a trend toward an increased risk of myocardial infarction, cardiovascular death, revascularization, angina, and all-cause mortality. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AVF, arteriovenous fistula; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; DBP, diastolic blood pressure; EPO, erythropoietin; ESRD, end-stage renal disease; MI, myocardial infarction; post-HD, post-dialysis; pre-HD, pre-dialysis; PVD, peripheral vascular disease; SBP, systolic blood pressure. a P-value between ACEI and ARB group after adjustment for the propensity score.
Kidney International (2011) 80, 978-985
We found that among hemodialysis patients initiated on two antihypertensive medications, combination ACEI and ARB treatment was associated with the highest risk of cardiovascular and all-cause mortality. Patients on an ARB without concomitant ACEI use had the lowest risk of cardiovascular death. In a subanalysis, among patients with preexisting CAD, combination ACEI þ ARB was superior to ACEI þ non-ARB but comparable to ARB þ non-ACEI.
The mechanism by which ARB alone or ARB-based combination therapy could lead to reduced cardiovascular mortality in patients with ESRD compared with ACEI-based combination therapy has not been well elucidated. A potential mechanism could be through the differential effects on oxidative stress and inflammation, which predict cardiovascular mortality in hemodialysis patients. 25, 26 During hemodialysis, contact of blood with the dialyzer and dialysate activates the kallikrein-kinin system and induces a systemic inflammatory reaction characterized by complement activation, leukocyte activation, and the generation of cytokines, with subsequent oxidative stress. 27, 28 By decreasing the formation or action of angiotensin II (Ang II), ACEIs and ARBs reduce oxidative stress and inflammation. 29 However, although ACEIs prevent the formation of Ang II, they also potentiate the actions of bradykinin by inhibiting its degradation and by altering B 2 receptor sensitivity. 30 Bradykinin induces fibrinolysis and stimulates inflammation. 31, 32 In hemodialysis patients with underlying endothelial dysfunction, chronic inflammation, and increased oxidative stress burden, 33 it is possible that the proinflammatory effects of bradykinin partially negate the beneficial effects of interrupting the renin-angiotensin system and reducing blood pressure. Models are covariate and propensity score adjusted. The scores were weighted using the inverse probability of treatment. Several limitations warrant mention. As this was an observational study, there may have been confounding by indication. Users of ACEIs were more likely to have risk factors for cardiovascular events. In contrast, blood pressure was significantly lower in ACEI users than in ARB users. Although adjustment for propensity score eliminated baseline differences between treatment groups and the analysis controlled for gender, it is possible that there may have been other differences that we did not measure. For example, we did not have patient medication histories during their pre-ESRD period and were not able to statistically adjust for such a factor. Some patients may have been treated in the past with ACEIs and ARBs, which were discontinued in the late stages of pre-ESRD to prevent further loss of glomerular filtration rate and acceleration of hemodialysis onset. In addition, we could not measure or adjust for the severity of baseline comorbidities (such as congestive heart failure), and this may have confounded the outcome. As information regarding comorbidities was obtained from the attending physician or transcribed from medical notes and could not be validated against diagnostics such as an echocardiogram, there could have been a misclassification bias. Therefore, the results should be considered as hypothesis generating and should lead to further randomized clinical trials. Finally, the ascertainment of cause of death was based on medical records and was susceptible to potential misclassification bias.
In summary, in a large cohort of ESRD patients undergoing maintenance hemodialysis, when more than one antihypertensive agent was added, ARB use was associated with a cardiovascular mortality benefit over ACEI therapy. Combination ACEI and ARB therapy was associated with the highest cardiovascular mortality. Randomized, prospective trials of ACEIs and ARBs in ESRD will provide valuable insight into the effects of different renin-angiotensin systeminhibiting agents in patients on dialysis.
METHODS
We executed two separate cohort analyses to examine the comparative effectiveness of ACEIs and ARBs with regard to mortality in a population of ESRD patients. In the first stage of the analysis, hemodialysis patients initiated on an ACEI were compared with patients started on an ARB. In a separate second stage of the analysis, stage 1 patients who progressed to combined ACEI plus ARB (ACEI þ ARB) therapy were compared with patients who were treated with renin-angiotensin system monotherapy (ACEI or ARB) plus a non-renin-angiotensin antihypertensive.
Population and data source All prevalent CHD patients from 1 January 1997 to 31 December 2003 from a large United States-based dialysis provider who met the study criteria were enrolled in this retrospective study. Eligible patients were identified through the querying of the electronic medical records, which also provided patient-level data on mortality, prescription medications, laboratory values, and demographic information for the analysis. During the study periods, patients receiving dialysis at an FMCNA (Fresenius Medical Care North America) clinic were asked to bring their prescription medication bottles to the dialysis clinic for reconciliation by nursing staff on admission to the clinic, post-hospitalization, or routinely once per month. Drug name, start date, and discontinuation date were updated in the electronic medical records at this time. Thus, oral medication records tracked all active prescriptions and over-thecounter medications prescribed by any physician from whom the patient had sought medical care in a wide range of health-care settings. All medication data were manually reviewed by a physician (KC) before inclusion in the study analysis. Full description of the electronic medical records system used for pharmacoepidemiological research has been provided in previous publications. [34] [35] [36] [37] Enrollment criteria All prevalent hemodialysis patients were enrolled in the analysis at the time of first prescription of an ACEI or ARB medication (that is, 'new user'), which was the study's interventional variable. 'New users' qualified only if the initiation of an ACEI or ARB was preceded by a 60-day 'washout period,' to prevent the inclusion of subjects in whom the prescription may have resulted from a carryover of previous ACEI or ARB therapy. During the 60-day 'washout period,' subjects were required to (1) have no ACEI or ARB use and (2) have no change in their other antihypertensive drugs.
After enrollment, subjects were followed for up to 2 years for mortality outcomes. Patients were censored users if they transferred out of the provider network, underwent transplantation, or recovered their renal function, when they could no longer be followed up for mortality outcomes within the FMCNA system. All analyses were conducted as intention to treat, such that subjects were analyzed according to their initial ACEI or ARB assignment, regardless of subsequent changes to their anti-hypertensive medication regime.
Outcome
The primary outcome of the study was defined as physiciandocumented death from coronary heart disease (myocardial infarction, sudden death, cardiac arrest, ventricular fibrillation), CAD (revascularization procedure), or vascular disease (disease of the aorta or peripheral vasculature). Secondary outcomes included all-cause mortality or death from stroke. Cause of death was ascertained from the attending nephrologist's diagnosis.
Statistical analysis
Baseline patient characteristics were ascertained as the most recent value on patient enrollment in the study. The distribution of baseline characteristics, by exposure group, was tabulated and compared using unadjusted and then propensity score-adjusted analysis of variance (ANOVA and ANCOVA, respectively) for continuous variables and logistic models for categorical variables. The propensity for the prescription of ACEI versus ARB was derived as a function of all baseline covariates (Table 2) using logistic regression. The scores were incorporated as inverse probability treatment weights in statistical models to balance for potential confounding by indication (see Supplementary Appendix 1 online) , 38, 39 as used in other studies. [40] [41] [42] We also directly compared the covariates between the ACEI and the ARB groups within quintiles of the propensity score (Supplementary Tables S2-S6 online) . We recognize there may have been other differences we did not measure.
Crude survival curves were obtained using the Kaplan-Meier method. Unadjusted HRs were initially derived using Cox regression without the inclusion of covariates or propensity score into the model. Covariate-adjusted survival curves (HR) were generated with the addition of propensity score weighting with further adjustment of 47 baseline patient characteristics (listed in the footnote to Table 2 ) when the ratio of events to covariates was o10 (ref. 43) . A group of patients receiving either ACEI or ARB (n ¼ 4880 in each treatment group) were matched on propensity score. HRs were also calculated for this matched cohort. Subgroup analysis by age, gender, race, vintage (years of chronic dialysis at study enrollment), diabetic status, presence of CAD, presence of congestive heart failure, past history stroke, and number of antihypertensive medications prescribed at study entry was also performed, as well as testing for effect modification through the addition of an interaction term (drug Â covariate) to the model. Statistical computations were accomplished with SAS version 9.1 (Cary, NC).
Second analysis: combined ACEI and ARB therapy A subpopulation of the original study cohort was further studied in a separate analysis to examine the effectiveness of combined (ACEI and ARB) versus one of the renin-angiotensin system-blocking therapies (either ACEI or ARB) one plus other antihypertensive drug. In particular, subjects who initially qualified for the ACEI versus ARB analysis outlined above were entered in a separate analysis if they continued their ACEI or ARB therapy and an additional antihypertensive medication was subsequently added. Thus, patients who were prescribed additional antihypertensive medications were classified according to the combination of their two antihypertensive medications (three exposure groups):
(1) ACEI þ ARB: the subject was started on an ACEI while continuing ARB therapy (or vice versa). (2) ACEI þ non-ARB: the subject was started on a non-reninangiotensin antihypertensive medication while continuing ACEI therapy. (3) ARB þ non-ACEI: the subject was started on a non-reninangiotensin antihypertensive medication while continuing ARB therapy.
Examples of a non-renin-angiotensin antihypertensive medication included a calcium channel blocker, a 1 -blocker, a 2 -agonist, b-blocker, hydralazine, minoxidil, or labetalol. For this analysis, baseline patient characteristics were ascertained at the initiation of the second antihypertensive therapy, and subjects were followed for up to 2 years from the time the additional antihypertensive medication was subsequently added. Except for the use of multinomial logistic regression for the propensity score calculation (that is, 42 exposure groups, see Supplementary Appendix S1 online), 44 outcomes, covariates, and statistical methods were otherwise identical to the analyses as outlined above. Propensity score matching was not performed in the second analysis because the three-group matching would result in a significantly reduced sample size. In addition, three-group propensity score matching has not been validated by the biostatistical literature and it is not supported by existing statistical software packages.
Adverse events
The relative time to hyperkalemia, in-center fall, and orthostatic hypotension by drug exposure group were also determined using covariate-and propensity score-adjusted Cox regression. The scores were weighted using the inverse probability of treatment. Hyperkalemia was defined as a predialysis serum potassium level of X6.5 mmol/l that was not accompanied by hemolysis. Orthostatic hypotension was defined as a X20 mm Hg decrease in systolic or X10 mm Hg decrease in diastolic blood pressure from the standing to sitting position after dialysis.
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